Skip to main content

Table 2 Ongoing clinical trials of targeted therapies combine with radiotherapy in HER2 + BCBM patients

From: Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases

NCT identifier

Study phase

Treatment

Primary end point

NCT04582968

Ib/II

Pyrotinib plus capecitabine combined with brain radiotherapy

Ib: safety and tolerability

II: intracranial local tumor control rate

NCT04767828

IV

Pyrrolidine maleate and capecitabine combined with brain radiotherapy

Time of intracranial tumor progression

NCT05042791

II

Radiation combined with pyrotinib and capecitabine

CNS-ORR

  1. BCBM breast cancer brain metastases, CNS central nervous system, ORR objective response rate